Changes

The vaccine mandates at school for [[HPV]] boosted NIH revenues:

The vaccine mandates at school for [[HPV]] boosted NIH revenues:

{{cquote|And the three best-selling products utilizing technology licensed from NIH [in 2014] were Janssen’s Prezista, a novel protease inhibitor for the treatment of HIV-1 in patients who are non-responsive to existing antiretroviral therapies, Merck’s Gardasil, a vaccine to protect against cervical cancer, and AstraZeneca’s Synagis, a monoclonal antibody for the treatment of Respiratory Syncytial Virus (RSV) in infants.<ref>https://www.raps.org/news-and-articles/news-articles/2019/4/how-biopharma-companies-use-nih-and-vice-versa</ref>}}

{{cquote|And the three best-selling products utilizing technology licensed from NIH [in 2014] were Janssen’s Prezista, a novel protease inhibitor for the treatment of HIV-1 in patients who are non-responsive to existing antiretroviral therapies, Merck’s [[Gardasil]], a vaccine to protect against cervical cancer, and AstraZeneca’s Synagis, a monoclonal antibody for the treatment of Respiratory Syncytial Virus (RSV) in infants.<ref>https://www.raps.org/news-and-articles/news-articles/2019/4/how-biopharma-companies-use-nih-and-vice-versa</ref>}}

== References ==

== References ==

{{reflist}}

{{reflist}}

{{coronavirus}}

{{coronavirus}}

[[category:patent law]]

[[category:patent law]]